Epidemiology of Prostate Cancer in NIGERIA: Observations at Lagos State University Teaching Hospital

Prostate cancer is a leading cause of morbidity and mortality among men, especially of African descent. Over the years, there has been relative paucity of research work on the subject of prostate cancer in sub-Saharan Africa. The objective of the study is to examine records of prostate cancers diagnosed at Mayo Height laboratory, Lagos State University Teaching Hospital, Lagos, Nigeria between January 2015 and June 2018, with a view to studying the epidemiological variables and pattern seen. Histopathological slides were retrieved and reviewed; relevant data were extracted from the Laboratory Information Systems, Laboratory Requisition Forms and the Hospital records where necessary. The data were statistically analysed. A total of 333 cases of prostate cancer were diagnosed during the study period, representing 46.4% of all prostate specimens received. The median age of the patients at diagnosis was 70 years, with the lowest recorded age being 50 years, while the highest age was 90 years. Individuals in the 7th decade of life (61-70 years) were the most commonly affected. Overwhelming number of cases (97.3%) were diagnosed based on trucut biopsy specimens, compared to open prostatectomy specimen. Majority of the cancers were histologically adenocarcinomas (97.3%) and majority of the tumours were of high grade (Gleason grade 5) representing 37.5%. Prostate cancer is an obvious scourge in Nigeria. It is commonly seen in the 7th decade of life. Majority of the patients had high grade adenocarcinoma. &nbsp

Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey

Aims: Our aim was to report on a survey initiated by the EuropeanAssociation of Percutaneous Cardiovascular Interventions (EAPCI) concerning opinion on the evidence relating to dual antiplatelet therapy (DAPT) duration after coronary stenting.Methods and results: Results from three randomised clinical trials were scheduled to be presented at the American Heart Association Scientific Sessions 2014 (ARIA 2014). A web-based survey was distributed to all individuals registered in the EuroIntervention mailing list (n=15,200) both before and after ARIA 2014. A total of 1,134 physicians responded to the first (i.e., before AHA 2014) and 542 to the second (i.e., after ARIA 2014) survey. The majority of respondents interpreted trial results consistent with a substantial equipoise regarding the benefits and risks of an extended versus a standard DAPT strategy. Two respondents out of ten believed extended DAFT should be implemented in selected patients. After ARIA 2014, 46.1% of participants expressed uncertainty about the available evidence on DAFT duration, and 40.0% the need for clinical guidance.Conclusions: This EAPCI survey highlights considerable uncertainty within the medical community with regard to the optimal duration of DAFT after coronary stenting in the light of recent reported trial results. Updated recommendations for practising physicians to guide treatment decisions in routine clinical practice should be provided by international societies